Literature DB >> 30477401

Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes.

Juliet Silberstein1, Philip D Harvey1,2.   

Abstract

INTRODUCTION: Individuals with schizophrenia present across a spectrum of symptomatology. Disability remains a debilitating reality across varying disease presentations and remains pervasive despite psychiatric medications. Cognition (neuro/social cognition) and negative symptoms have emerged as the strongest predictors of real-world disability, but account for <50% of the variance in outcomes.
METHODS: Our attempts to determine what accounts for the remaining 50% of variance has shown that poor introspective accuracy (IA) may be the most potent predictor of functional outcomes 25% of individuals with schizophrenia. We define IA as the adequacy of self-assessments of ability, skills, performance, or decisions. We suggest that IA is a progression of metacognition and can extend beyond cognition to include misestimation of prior and likely future performance in social or other adaptively relevant situations.
RESULTS: Additionally, IA is bidirectional and self-orientated. Emerging research has found that IA of neurocognitive ability better predicts everyday functional deficits than scores on performance-based measures or neurocognitive skills and has found that IA of social cognition accounts unique variance in real-world disability above social cognitive performance. DISCUSSION: We argue that impaired IA, affecting 25-50% of patients with schizophrenia, in the absence or minimal presence of other impairments might be the most powerful predictor of functional outcomes.

Entities:  

Keywords:  Schizophrenia; metacognition; neurocognition; social cognition

Mesh:

Year:  2018        PMID: 30477401      PMCID: PMC6370513          DOI: 10.1080/13546805.2018.1549985

Source DB:  PubMed          Journal:  Cogn Neuropsychiatry        ISSN: 1354-6805            Impact factor:   1.871


  59 in total

1.  Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study.

Authors:  Amy E Pinkham; David L Penn; Michael F Green; Philip D Harvey
Journal:  Schizophr Bull       Date:  2015-05-04       Impact factor: 9.306

2.  Self-assessment of functional status in schizophrenia.

Authors:  Christopher R Bowie; Elizabeth W Twamley; Hannah Anderson; Brooke Halpern; Thomas L Patterson; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2006-10-02       Impact factor: 4.791

3.  Assessing everyday functioning in schizophrenia: not all informants seem equally informative.

Authors:  Samir Sabbag; Elizabeth M Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson; Philip D Harvey
Journal:  Schizophr Res       Date:  2011-05-26       Impact factor: 4.939

4.  Self-assessment of social cognitive ability in schizophrenia: Association with social cognitive test performance, informant assessments of social cognitive ability, and everyday outcomes.

Authors:  Juliet M Silberstein; Amy E Pinkham; David L Penn; Philip D Harvey
Journal:  Schizophr Res       Date:  2018-04-17       Impact factor: 4.939

5.  Self-assessment of functional ability in schizophrenia: milestone achievement and its relationship to accuracy of self-evaluation.

Authors:  Felicia Gould; Samir Sabbag; Dante Durand; Thomas L Patterson; Philip D Harvey
Journal:  Psychiatry Res       Date:  2013-03-26       Impact factor: 3.222

6.  A comparison of insight into clinical symptoms versus insight into neuro-cognitive symptoms in schizophrenia.

Authors:  Alice Medalia; Julie Thysen
Journal:  Schizophr Res       Date:  2009-10-17       Impact factor: 4.939

7.  Response confidence for emotion perception in schizophrenia using a Continuous Facial Sequence Task.

Authors:  Steffen Moritz; Aneta Woznica; Christina Andreou; Ulf Köther
Journal:  Psychiatry Res       Date:  2012-08-21       Impact factor: 3.222

8.  Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms.

Authors:  Christopher R Bowie; Abraham Reichenberg; Thomas L Patterson; Robert K Heaton; Philip D Harvey
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

9.  Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies.

Authors:  Dante Durand; Martin Strassnig; Samir Sabbag; Felicia Gould; Elizabeth W Twamley; Thomas L Patterson; Philip D Harvey
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-25       Impact factor: 4.600

10.  Cost of schizophrenia in England.

Authors:  Roshni Mangalore; Martin Knapp
Journal:  J Ment Health Policy Econ       Date:  2007-03
View more
  17 in total

1.  Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning.

Authors:  Philip D Harvey; Elizabeth Deckler; Mackenzie T Jones; L Fredrik Jarskog; David L Penn; Amy E Pinkham
Journal:  J Psychiatr Res       Date:  2019-05-10       Impact factor: 4.791

2.  Social cognition, neurocognition, symptomatology, functional competences and outcomes in people with schizophrenia - A network analysis perspective.

Authors:  Michal Hajdúk; David L Penn; Philip D Harvey; Amy E Pinkham
Journal:  J Psychiatr Res       Date:  2021-09-24       Impact factor: 4.791

3.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

Review 4.  Examining older adults with neuroatypical conditions for MCI/dementia: Barriers and recommendations of the Neuroatypical Conditions Expert Consultative Panel.

Authors:  Matthew P Janicki; James A Hendrix; Philip McCallion
Journal:  Alzheimers Dement (Amst)       Date:  2022-07-08

5.  Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study.

Authors:  Ellaheh Gohari; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey
Journal:  Psychiatry Res       Date:  2022-02-25       Impact factor: 11.225

6.  Overconfidence in social cognitive decision making: Correlations with social cognitive and neurocognitive performance in participants with schizophrenia and healthy individuals.

Authors:  Michelle M Perez; Bianca A Tercero; David L Penn; Amy E Pinkham; Philip D Harvey
Journal:  Schizophr Res       Date:  2020-10-21       Impact factor: 4.939

7.  Self-reported social functioning and social cognition in schizophrenia and bipolar disorder: Using ecological momentary assessment to identify the origin of bias.

Authors:  Dante Durand; Martin T Strassnig; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey
Journal:  Schizophr Res       Date:  2021-03-02       Impact factor: 4.939

8.  Myospryn deficiency leads to impaired cardiac structure and function and schizophrenia-associated symptoms.

Authors:  Ioanna Kostavasili; Ismini Kloukina; Elsa Tsoupri; Mary Tsikitis; Despoina Miliou; Eleni Vasilaki; Aimilia Varela; Modestos Nakos-Bimpos; Constantinos Davos; Manolis Mavroidis; Alexia Polissidis; Yassemi Capetanaki
Journal:  Cell Tissue Res       Date:  2021-05-26       Impact factor: 5.249

9.  Ecological momentary facial emotion recognition in psychotic disorders.

Authors:  Colin A Depp; Snigdha Kamarsu; Tess F Filip; Emma M Parrish; Philip D Harvey; Eric L Granholm; Samantha Chalker; Raeanne C Moore; Amy Pinkham
Journal:  Psychol Med       Date:  2021-01-12       Impact factor: 10.592

10.  Using a Meta-cognitive Wisconsin Card Sorting Test to measure introspective accuracy and biases in schizophrenia and bipolar disorder.

Authors:  Bianca A Tercero; Michelle M Perez; Noreen Mohsin; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2021-06-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.